Professional Documents
Culture Documents
Case Study 3
Case Study 3
Case Study 3
PHINMA
PATIENT DATA
Name: C.C.M.
Age: 28 yrs. old
Gender: Female
Address: 356 Nasipit Talamban, Cebu City
Birth Date: August 1, 1992
Birth Place: Cebu City
Occupation: Housewife
Marital Status: Married
Religion: Jehovah’s Witness
Vital Signs
BP: 100/70
HR: 95
RR: 18
Temp: 36.4
O2 Sat: 98%
Upper and Lower Extremities: muscles, (+) hypo gastric pain radiating to the
bones and left sacrum anterior with a pain score
joints. of 1/10.
LABORATORY TEST
Date Type of Patient’s Normal Significance/
exam Result Values Interpretation
Urine Macroscopic
Analysis Examination Macroscopic Within normal
Color: Yellow Examination range
Transparency: Color: Pale
Clear yellow to
Volume: 50 mL deep amber
Specific Transparency:
Gravity: 1.015 Clear or
Chemical slightly cloudy
Examination Specific
Albumin: Gravity:
Negative pH: 1.005-1.30
6.5 Chemical
Ketone: Examination
Negative Albumin: Less
Blood: than 30 mg
Negative pH: 4.5-8
Glucose: Ketone: Less
Negative than .6
Nitrite: Blood: 4
Negative Glucose:
Bilirubin: Negative
Negative Nitrite:
Urobilinogen: Negative
Normal Bilirubin:
Microscopic Negative
Examination Urobilinogen:
WBC: 1-3/HPF 1mg/dl
RBC: 5-7/HPF Microscopic
Epithelial Examination
Cells: WBC: >10
Moderate RBC: <5
Mucus Thread: Epithelial
Few Cells: <5
Bacteria: Few Mucus Thread:
Negative
Bacteria:
Absent
Amorphous
Phosphates:
Normal
CBC WBC: 11.80 WBC: 4.4 - Within normal
NEU: 67.8 11.0 range
LYM: 21.1 NEU: 37.0 -
MON: 9.4 80.0
LYM: 10.0 -
50.0
EOS: 1.3 MON: 0.0 -
BAS: 0.4 12.0
RBC: 3.96
HGB: 12.1 EOS: 0.0 - 7.0
HCT: 36.1 BAS: 0.0 - 2.5
MCV: 91 RBC: 4.5 - 5.1
MCH: 30.5 HGB: 12.3 -
MCHC: 33.5 15.3
RDW: 13.0 HCT: 35.9 -
PLT: 212 44.6
MPV: 7.4 MCV: 80 - 96
MCH: 27.5 -
33.2
MCHC: 32.0 -
36.0
RDW: 11.6 -
14.8
PLT: 150 - 450
MPV: 6.0 -
11.0
DIAGNOSTIC TEST
Date Type of Patient’s Result Significance/
exam Interpretation
05/14/20 X-ray Lung Normal
Report fields are clear.
Heart is
not enlarged. The
pulmonary vascular
markings are within
normal limits. Both
hemidiaphragms
and costophrenic
sulci are sharp
and distinct.
The visualized
osseous structures
are unremarkable.
DRUG STUDY
Name of Mechanism of Indication Adverse Nursing
Drug Action Effects Responsibilitie
s
s
Generic Inhibits Treatment of CNS: Before:
Name: histamine active duodenal confusion, 1. Baseline
Ranitidine action ulcers and dizziness, Assessment:
Brand at histamine gastroesophage drowsiness, Receive full
Name: H2-receptors of al reflex hallucinations, medication
Zantac gastric disease(GERD). headache history and
Classificatio Parietal Management of CV: screen for
n: cells.Therapeut Gastric hyper arrhythmia s contraindication
H2 blockers ic secretory GI: s
Dosage: 50 Effect: states constipation, .
mg Inhibits IV: diarrhea, 2.Question
Route: gastric Prevention drug-induced history of
IVTT acid and hepatitis, hepatic
Frequency: secretion. treatment of nausea impairment,
Now Reduces upper GI bleed. GU: long
gastric decreased QT syndrome.
volume, Contraindicati sperm
hydrogen Ion on count, During:
Concentration. ns impotence 1. Administer
Hypersensitivity Endo: drug.
to gynecomastia 2. Record onset,
ranolazine. Heat: type, radiation,
Hepatic agranulocytosi location,intensit
cirrhosis, s, y, duration of
concurrent use a plastic inguinal pain,
of strong anemia precipitating
CYP3A MISC: factors.
inhibitors pr hypersensitivit 3. Obtain
VYP3A inducers y baseline EKG
reactions After:
1.Interventions/
Ev
valuation: Assist
with ambulation
if dizziness
occurs.
Give with food
if nausea occurs
FDAR
Date Focus Time DAR
Vital Signs:
A: Encourage the pt
to do deep
breathing exercises
and relaxation
techniques.
Perform a
comprehensive
assessment of
pain. Provide non
pharmacologic pain
management.
Provide
pharmacologic pain
management as
ordered. Provide
health teachings
based on the
patient’s condition.
R: The patient
verbalized that
pain was
minimized and
relieved.
DISCHARGE PLANNING
Date Focus Time DAR
Medication: The
client knows the
name, action,
purpose, dose,
route of
administration, and
side effects of each
drug she is taking.
The client is
instructed to report
or contact the
physician if adverse
reactions are
present.
- Cefuroxime
( Altoxime) 500
mg 1 tab BID
P.O./ 6 more
days -
Mefenamic Acid
(Almefen) 500
mg 1 cap q 6ᵒ
- MV + Iron (Beniforte)
1 cap OD P.O./ x 3
months
- Calcium
+ Vit. D
( Osteo-D)
1 tab BID
P.O./ x 3
months -
Vitamin C
(Alto Cee)
1 tab OD
P.O./ x 1
month.
Environment: The
client knows the
importance of
having a clean,
comfortable, and
healthy
environment free
from any actual or
potential hazards.
This can contribute
to the client’s
improvement of her
health condition.
Homemaking
services; and
emotional and
economic support
systems are in
place.
Treatment: The
client and family will
know the purpose
and action of any
treatment.
Take-home
medications are
vital for the
improvement of the
client’s condition.
Health Teaching:
Provide incision care.
Shower as needed. Pat
your incision dry. Watch
your incision for signs
of infection, like more
redness or drainage.
Hold a pillow against
the incision when you
laugh or cough and
when you get up from a
lying or sitting position.
Remember, it can take
as long as 6 weeks for
your incision to heal.
Outpatient Phone
follow-up on May 13,
2020, via RITU